Press Releases - Exact Sciences
WEB5 days ago · Exact Sciences Announces Second-Quarter 2024 Results. July 17, 2024. Exact Sciences Awards Grants to 28 Organizations Focused on Increasing Colorectal Cancer Screening. May 24, 2024. Exact Sciences Demonstrates Continued Leadership in Early Cancer Diagnosis and Improved Health Outcomes for Patients with Multiple Data Presentations at ASCO®.
Exact Sciences’ colon cancer blood test shows initial promise - STAT
WEB5 days ago · By Jonathan Wosen. Sept. 16, 2024. West Coast Biotech & Life Sciences Reporter. Exact Sciences, which has for years sold a stool-based colon cancer test, on Monday announced that a blood-based ...
Exact Sciences says data support its colon cancer blood test
WEB5 days ago · Exact Sciences released data from a study of its blood-based colorectal cancer screening test that showed sensitivities of 88.3% for colorectal cancer and 31.2% for advanced precancerous lesions. Specificity, a measure of how well a test identifies people who do not have cancer, was 90.1% for negative samples confirmed by colonoscopy.
Exact Sciences Presents Data Demonstrating Advancement in …
WEB5 days ago · MADISON, Wis., September 16, 2024--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced performance data for its blood-based colorectal ...
Buy Rating Affirmed for Exact Sciences on Robust CRC Test …
WEB5 days ago · Exact Sciences (EXAS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today.Analyst Mark Massaro from BTIG reiterated a Buy rating on the stock and has a ...
News & Stories - Exact Sciences
WEBAug 20, 2024 · The Unseen Consequence of Covid-19 on Cancer Screenings. Don’t Let Age Fool You: Early Onset Colorectal Cancer is On the Rise. The Truth About Cancer: Debunking Five Myths about the Big C. Unlocking the Future of Cancer Diagnostics: Powerful Decision-Making to Enhance Patient Impact.
Exact Sciences Announces Fourth Quarter 2023 Results
WEBMADISON, Wis., Feb. 21, 2024 — Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $647 million for the fourth quarter of 2023 and $2.50 billion for the full year of 2023, both ended Dec. 31, 2023.
Exact Sciences Announces Preliminary Fourth Quarter 2023 Results
WEBJan 7, 2024 · Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company expects to report revenue between $645.5 million and $647.5...
Exact Sciences Advances Early Cancer Detection and Precision …
WEBOct 20, 2023 · Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it will present new data supporting the company's research in early cancer...
Exact Sciences Blood-Based Colon Cancer Screening Data at …
WEB5 days ago · In morning trade on the Nasdaq, Exact Sciences' shares were up about 4 percent at $68.16 on the news. In a presentation at the European Society for Medical Oncology Congress, the firm described results of a study that included more than 3,000 blood samples, including approximately 2,900 blinded, prospectively collected samples from …
- Some results have been removed
Skip to content